The preclinical discovery of amyotrophic lateral sclerosis drugs

Expert Opinion on Drug Discovery

Volumn 6, Issue 11, 2011, Pages 1127-1138

  Glicksman, Marcie A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

genetic diseases; motoneuron disease; neurodegeneration; stem cells; therapeutic strategies

Indexed keywords

CHELATING AGENT; CK 2017357; DEXPRAMIPEXOLE; GROWTH FACTOR; OLESOXIME; PRAMIPEXOLE; RILUZOLE; RNA; SNN 0029; UNCLASSIFIED DRUG; VACCINE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; GENETIC SUSCEPTIBILITY; HUMAN; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 80755130602     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.628654     Document Type: Review

References (82)

1. Available from: http://www.ninds.nih. gov/disorders/ amyotrophiclateralsclerosis/ detail-ALS.htm
2. Bosco DA, Landers JE. Genetic determinants of Amyotrophic Lateral Sclerosis as therapeutic targets, [review]. CNS Neurol Disord Drug Targets 2010;9:779-90
3. Perry JJ, Shin DS, Tainer JA. Amyotrophic lateral sclerosis, [review]. Adv Exp Med Biol 2010;685:9-20
4. Bento-Abreu A, Van Damme P, Van Den Bosch L, et al. The neurobiology of amyotrophic lateral sclerosis, [review]. Eur J Neurosci 2010;31:2247-65
5. Kuzma-Kozakiewicz M, Kwiecinski H. The genetics of amyotrophic lateral sclerosis, [review]. Neurol Neurochir Pol 2009;43:538-49
6. Cheah BC, Vucic S, Krishnan AV, et al. Riluzole, neuroprotection and amyotrophic lateral sclerosis, [review]. Curr Med Chem 2010;17:1942-199
7. Doble A. The pharmacology and mechanism of action of riluzole, [review]. Neurology 1996;47:S233-41
8. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-3 (Pubitemid 44547757)
9. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/ TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323:1205-8
10. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323:1208-11
11. Ticozzi N, Tiloca C, Morelli C, et al. Genetics of familial Amyotrophic lateral sclerosis, [review]. Arch Ital Biol 2011;149:65-82
12. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Ann Rev Neurosci 2004;27:723-49 (Pubitemid 39050419)
13. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006;52:39-59 (Pubitemid 44466358)
14. Available from: http://clinicaltrials.gov/
15. Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), [review]. Cochrane Database Syst Rev 2007;24:CD001447
16. Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116:2290-6 (Pubitemid 44162339)
17. Martin LJ. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010;13:568-80
18. Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007;322:709-20 (Pubitemid 47105813)
19. Deng HX, Biglio EH, Zhai H, et al. Differential involvement of optineurin in amyotrophic lateral sclerosis with or without SOD1 mutations. Arch Neurol 2011;68:1057-61
20. Udan M, Baloh RH. Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion 2011;5:1-5
21. Xia G, Benmohamed R, Kim J, et al. Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. J Med Chem 2011;547:2409-21
22. Benmohamed R, Arvanites AC, Kim J, et al. Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011;12:87-96
23. Luo W, Sun W, Taldone T, et al. Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener 2010;5:24
24. Ray SS, Nowak RJ, Brown RH, et al. Small molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci USA 2005;102(10):3639-44 (Pubitemid 40354664)
25. Bao R, Lai CJ, Qu H, et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res 2009;15:4046-57
26. Schmalbach S, Petri S. Histone deacetylation and motor neuron degeneration. CNS Neurol Disord Drug Targets 2010;9:279-84
27. d'Ydewalle C, Krishnan J, Chiheb DM, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 2011;17:968-74
28. Markert CD, Kim E, Gifondorwa DJ, et al. A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis. J Med Food 2010;13:1081-5
29. Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007;26:3169-79 (Pubitemid 47057498)
30. Shukla DK, Kaiser CC, Stebbins GT, et al. Effects of pioglitazone on diffusion tensor imaging indices in multiple sclerosis patients. Neurosci Lett 2010;472:153-6
31. Schutz B, Reimann J, Dumitrescu-Ozimek L, et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 2005;25:7805-12 (Pubitemid 41208652)
32. Shibata N, Yamamoto T, Hiroi A, et al. Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1-mutated amyotrophic lateral sclerosis. Neuropathology 2010;30:353-60
33. Kiaei M, Kipiani K, Chen J, et al. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005;191:331-6 (Pubitemid 40092877)
34. Kleinschnitz C, Grund H, Wingler K, et al. Post-stroke inhibition of inducedNADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 2010;8-13
35. Hill S, Hirano K, Shmanai VV, et al. Isotope-reinforced polyunsaturated fatty acids protect yeast cells from oxidative stress. Free Radic Biol Med 2011;50:130-8
36. Appel SH, Zhao W, Beers DR, et al. The microglial-motoneuron dialogue in ALS, [review]. Acta Myol 2011;30:4-8
37. Di Giorgio FP, Boulting GL, Bobrowicz S, et al. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 2008;3:637-48
38. Available from: http://www.als.net/ OurResearch/CurrentPipeline.aspx
39. Mackenzie R, Kiernan M, McKenzie D, et al. Hyperimmune goat serum for amyotrophic lateral sclerosis. J Clin Neurosci 2006;13:1033-6 (Pubitemid 44750672)
40. Mackenzie RA. Follow-up study of hyper-immune goat serum (Aimspro) for amyotrophic lateral sclerosis (ALS). J Clin Neurosci 2009;16:1508-9
41. ALSUntangled No. 7: Investigating hyperimmune goat serum (Aimspro) for ALS. Amyotroph Lateral Scler 2010;11:571-3
42. Zhong Z, Ilieva H, Hallagan L, et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest 2009;119:3437-49
43. Bar-Am O, Amit T, Weinreb O, et al. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J Alzheimers Dis 2010;21:361-71
44. Teichberg VI. GOT to rid the body of excess glutamate. J Cereb Blood Flow Metab 2011;31:1376-7
45. Zlotnik A, Gruenbaum SE, Artru AA, et al. The neuroprotective effects of oxaloacetate in closed head injury in rats is mediated by its blood glutamate scavenging activity: evidence from the use of maleate. J Neurosurg Anesthesiol 2009;21:235-41
46. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25 (Pubitemid 20222147)
47. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-8
48. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
49. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16:675-86 (Pubitemid 26103145)
50. Bendotti C, Tortarolo M, Suchak SK, et al. SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem 2001;79:737-46 (Pubitemid 33086511)
51. Colton CK, Kong Q, Lai L, et al. Identification of translational activators of glial glutamate transporter EAAT2 through cell-based highthroughput screening: an approach to prevent excitotoxicity. J Biomol Screen 2010;15:653-62
52. Xing X, Chang LC, Kong Q, et al. Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg Med Chem Lett 2011;21:5774-7
53. Diogenes MJ, Outeiro TF. Neurotrophic factors as a protective strategy in Parkinson's disease. CNS Neurol Disord Drug Targets 2010;9:754-63
54. Yang T, Knowles JK, Lu Q, et al. Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS One 2008;3:e3604
55. Hellman M, Arumae U, Yu LY, et al. Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons, Exp. Neurol 2011;228:99-108
56. Rizvanov AA, Guseva DS, Salafutdinov II, et al. Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice. Exp Biol Med (Maywood) 2011;236:91-8
57. Visanji NP, Orsi A, Johnston TH, et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 2008;22:2488-97 (Pubitemid 351948666)
58. Liu NK, Xu XM. MicroRNA in central nervous system trauma and degenerative disorders,. Physiol Genomics 2011;43:571-80
59. Lee ST, Chu K, Im WS, et al. Altered microRNA regulation in Huntington's disease models. Exp Neurol 2011;227:172-9
60. Wang H, Liu J, Zong Y, et al. miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-beta type II receptor. Brain Res 2010;1357:166-74
61. Haramati S, Chapnik E, Sztainberg Y, et al. miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci USA 2010;107:13111-16
62. Williams AH, Valdez G, Moresi V, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009;326:1549-54
63. Maragakis NJ. Stem cells and the ALS neurologist. Amyotroph Lateral Scler 2010;11:417-23
64. Silani V, Calzarossa C, Cova L, et al. Stem cells in amyotrophic lateral sclerosis: motor neuron protection or replacement? CNS Neurol Disord Drug Targets 2010;9:314-24
65. Mazzini L, Vercelli A, Ferrero I, et al. Stem cells in amyotrophic lateral sclerosis: state of the art. Expert Opin Biol Ther 2009;9:1245-58
66. Fornai F, Meininger V, Silani V. Future therapeutical strategies dictated by pre-clinical evidence in ALS. Arch Ital Biol 2011;149:169-74.81
67. Takeuchi S, Fujiwara N, Ido A, et al. Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J Neuropathol Exp Neurol 2010;69:1044
68. Angelov DN, Waibel S, Guntinas-Lichius O, et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2003;100:4790-5 (Pubitemid 36457807)
69. Rutkove S. Electrical impedance myography as a biomarker for ALS. Lancet Neurol 2009;8:226; author reply 227
70. Baltadzhieva R, Gurevich T, Korczyn AD. Autonomic impairment in amyotrophic lateral sclerosis. Curr Opin Neurol 2005;18:487-93 (Pubitemid 41476132)
71. Siddique N, Siddique T. Genetics of amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am 2008;19(3):429-39 (Pubitemid 351958484)
72. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218-21
73. Bull ND, Martin KR. Towards stem cell-based therapies for retinal neurodegenerative diseases. Stem Cells 2011;676
74. Dyson SC, Barker RA. Cell-based therapies for Parkinson's disease. Expert Rev Neurother 2011;11:831-44
75. Available from: http://clinicaltrials.gov, identifier no. NCT00875654
76. Harting MT, Jimenez F, Xue H, et al. Intravenous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg 2009;110:1189-97
77. Turner MR, Modo M. Advances in the application of MRI to amyotrophic lateral sclerosis. Expert Opin Med Diagn 2010;4:483-96
78. Agosta F, Chio A, Cosottini M, et al. The present and the future of neuroimaging in amyotrophic lateral sclerosis, [review]. AJNR Am J Neuroradiol 2010;31:1769-77
79. Pradat PF, Dib M. Biomarkers in amyotrophic lateral sclerosis: facts and future horizons, [review]. Mol Diagn Ther 2009;13:115-25
80. Turner MR, Kiernan MC, Leigh PN, et al. Biomarkers in amyotrophic lateral sclerosis, [review]. Lancet Neurol 2009;8:94-109
81. Sussmuth SD, Brettschneider J, Ludolph AC, et al. Biochemical markers in CSF of ALS patients, [review]. Curr Med Chem 2008;15:1788-801
82. Wegorzewska I, Bell S, Baloh RH, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 2009;106:18809-14